Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].

Bulletin du cancer - 1 Jan 2008

Lièvre Astrid, Laurent-Puig Pierre

Abstract excerpt

Among the targeted therapies used in the treatment of metastatic colorectal cancer (CRC), cetuximab was registered in France in 2004. This chimeric antibody inhibiting the Epidermal Growth receptor (EGFR) has been demonstrated to be efficient in the treatment of irinotecan-resistant metastatic CRC expressing the EGFR. Panitumumab, a fully humanized anti-EGFR antibody should soon be registered after failure of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Cetuximab
Share to Cyclin D1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Eruptions

Share to Epidermal Growth Factor

Share to Irinotecan

Share to Panitumumab

Share to Receptors, IgG

Source

Identifiers

PMID: 18230579
DOI: 10.1684/bdc.2008.0551

Genes

EGFR
EGF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].PMID 18230579Read ↗

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.Semantic proximity Read ↗

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Semantic proximity Read ↗

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.Semantic proximity Read ↗

[Prediction of EGFR blockade responses in metastatic colorectal carcinoma].Semantic proximity Read ↗

[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].Semantic proximity Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Semantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

[Molecular targets for colon cancer. VEGF, EGFR - and what else?].Semantic proximity Read ↗

Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.